Spyre Therapeutics, Inc. (SYRE)
Largest Insider Buys in Sector
SYRE Stock Price History Chart
SYRE Stock Performance
About Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) …
Insider Activity of Spyre Therapeutics, Inc.
Over the last 12 months, insiders at Spyre Therapeutics, Inc. have bought $0 and sold $779,316 worth of Spyre Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Spyre Therapeutics, Inc. have bought $0 and sold $779,316 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
List of Insider Buy and Sell Transactions, Spyre Therapeutics, Inc.
| 2024-11-06 | Sale | director | 6,700 0.0148% | $36.76 | $246,313 | -26.43% | ||
| 2024-10-25 | Sale | director | 300 0.0007% | $36.43 | $10,929 | -20.08% | ||
| 2024-09-03 | Sale | Chief Financial Officer | 18,531 0.0313% | $28.17 | $522,074 | +7.48% |